Schizophrenia - Pipeline Review

H2 2011

Product Code GMD16896
Publication Date September 2011
Publisher Global Markets Direct
Product Type Report
Pages 121
ISBN Number not applicable
Change currency
PDF £315.00 €379 $498 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Schizophrenia - Pipeline Review

H2 2011

Schizophrenia - Pipeline Review, H2 2011

Summary

Global Markets Direct's, 'Schizophrenia - Pipeline Review, H2 2011', provides an overview of the Schizophrenia therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizophrenia. 'Schizophrenia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Schizophrenia.
  • A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Schizophrenia pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Schizophrenia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Schizophrenia therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

  • Introduction
    • Global Markets Direct Report Coverage
    • Schizophrenia Overview
    • Therapeutics Development
    • An Overview of Pipeline Products for Schizophrenia
    • Schizophrenia Therapeutics under Development by Companies
    • Schizophrenia Therapeutics under Investigation by Universities/Institutes
    • Late Stage Products
    • Comparative Analysis
    • Mid Clinical Stage Products
    • Comparative Analysis
    • Early Clinical Stage Products
    • Comparative Analysis
    • Discovery and Pre-Clinical Stage Products
    • Comparative Analysis
    • Schizophrenia Therapeutics - Products under Development by Companies
    • Schizophrenia Therapeutics - Products under Investigation by Universities/Institutes
    • Companies Involved in Schizophrenia Therapeutics Development
    • DURECT Corporation
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • NsGene A/S
    • Amgen Inc
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Alkermes, Inc
    • Merck & Co., Inc
    • Dainippon Sumitomo Pharma Co., Ltd
    • Taisho Pharmaceutical Co., Ltd
    • Albany Molecular Research, Inc
    • BioLineRx, Ltd
    • Avineuro Pharmaceuticals, Inc
    • Alexza Pharmaceuticals, Inc
    • Neurocrine Biosciences, Inc
    • Novartis AG
    • EnVivo Pharmaceuticals
    • Daewoong Pharmaceutical Co., Ltd
    • Gedeon Richter Plc
    • H Lundbeck A/S
    • Orion Corporation
    • Pfizer Inc
    • Shire Plc
    • Addex Pharmaceuticals
    • Evotec Aktiengesellschaft
    • IntelGenx Technologies Corp
    • Galenea Corp
    • Marinus Pharmaceuticals, Inc
    • M's Science Corporation
    • BrainCells Inc
    • EUSA Pharma, Inc
    • KemPharm, Inc
    • Heptares Therapeutics Ltd
    • BIOPROJET SCR
    • Reviva Pharmaceuticals Inc
    • SK Bio-Pharmaceuticals
    • PharmaNeuroBoost N.V
    • Schizophrenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
    • Late Stage Drug Profiles
    • Zicronapine - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Latuda - Drug Profile
    • RG1678 - Drug Profile
    • Vyvanse - Drug Profile
    • Aripiprazole - Drug Profile
    • Cariprazine - Drug Profile
    • BL-1020 - Drug Profile
    • Bifeprunox - Drug Profile
    • LY2140023 - Drug Profile
    • AZ-004 - Drug Profile
    • Glycine - Drug Profile
    • Amantadine - Drug Profile
    • Acamprosate - Drug Profile
    • Ondansetron - Drug Profile
    • Risperidone + Dextromethorphan - Drug Profile
    • Memantine - Drug Profile
    • Quetiapine - Drug Profile
    • Navoban + Risperdal - Drug Profile
    • Pregnenolone - Drug Profile
    • Gabitril - Drug Profile
    • D Serine - Drug Profile
    • Levosulpiride - Drug Profile
    • RO4917838 - Drug Profile
    • Bexarotene - Drug Profile
    • D Serine - Drug Profile
    • Raloxifene - Drug Profile
    • Schizophrenia Therapeutics - Drug Profile Updates
    • Schizophrenia Therapeutics - Discontinued Products
    • Schizophrenia - Featured News
    • Aug 23, 2011: Sunovion Pharmaceuticals Canada Receives Health Canada Acceptance Of Lurasidone New Drug Submission For Treatment Of Schizophrenia
    • Aug 19, 2011: Alexza Provides Regulatory Update On ADASUVE
    • Aug 05, 2011: Alexza Announces Resubmission Of AZ-004 NDA
    • Aug 04, 2011: Allon Receives US Patent For Davunetide As Treatment For Schizophrenia
    • Jul 26, 2011: EMA Accepts Vanda's MAA For Oral Iloperidone Tablets
    • Jul 25, 2011: Biotie Advances Clinical Program Of SYN120 With Imaging Study At Johns Hopkins Center Of Excellence
    • Jul 13, 2011: Newron Submits IND For NW-3509 For Patients With Schizophrenia
    • Jun 30, 2011: Alkermes Announces Positive Results From Clinical Study Of ALKS 9070 For Treatment Of Schizophrenia
    • Jun 28, 2011: BioLineRx Announces Enrollment Of First Patient In Phase II/III CLARITY Clinical Trial For BL-1020
    • Jun 23, 2011: Neurocrine Biosciences Announces Notice Of Allowance For Composition Of Matter Patent On VMAT2 Inhibitor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
  • List of Tables
    • Number of Products Under Development for Schizophrenia, H2 2011
    • Products under Development for Schizophrenia - Comparative Analysis, H2 2011
    • Number of Products under Development by Companies, H2 2011
    • Number of Products under Development by Companies, H2 2011
    • Number of Products under Development by Companies, H2 2011
    • Number of Products under Investigation by Universities/Institutes, H2 2011
    • Number of Products under Investigation by Universities/Institutes, H2 2011
    • Comparative Analysis by Late Stage Development, H2 2011
    • Comparative Analysis by Mid Clinical Stage Development, H2 2011
    • Comparative Analysis by Early Clinical Stage Development, H2 2011
    • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Investigation by Universities/Institutes, H2 2011
    • Products under Investigation by Universities/Institutes, H2 2011
    • Products under Investigation by Universities/Institutes, H2 2011
    • DURECT Corporation, H2 2011
    • Johnson & Johnson, H2 2011
    • F. Hoffmann-La Roche Ltd., H2 2011
    • Abbott Laboratories, H2 2011
    • NsGene A/S, H2 2011
    • Amgen Inc., H2 2011
    • Eli Lilly and Company, H2 2011
    • GlaxoSmithKline plc, H2 2011
    • Alkermes, Inc., H2 2011
    • Merck & Co., Inc., H2 2011
    • Dainippon Sumitomo Pharma Co., Ltd., H2 2011
    • Taisho Pharmaceutical Co., Ltd., H2 2011
    • Albany Molecular Research, Inc., H2 2011
    • BioLineRx, Ltd., H2 2011
    • Avineuro Pharmaceuticals, Inc., H2 2011
    • Alexza Pharmaceuticals, Inc., H2 2011
    • Neurocrine Biosciences, Inc., H2 2011
    • Novartis AG, H2 2011
    • EnVivo Pharmaceuticals, H2 2011
    • Daewoong Pharmaceutical Co., Ltd., H2 2011
    • Gedeon Richter Plc., H2 2011
    • H Lundbeck A/S, H2 2011
    • Orion Corporation, H2 2011
    • Pfizer Inc., H2 2011
    • Shire Plc, H2 2011
    • Addex Pharmaceuticals, H2 2011
    • Evotec Aktiengesellschaft, H2 2011
    • IntelGenx Technologies Corp., H2 2011
    • Ligand Pharmaceuticals Incorporated, H2 2011
    • NeuroSearch A/S, H2 2011
    • NPS Pharmaceuticals, Inc., H2 2011
    • Nuvo Research Inc., H2 2011
    • ACADIA Pharmaceuticals Inc., H2 2011
    • Jazz Pharmaceuticals, Inc., H2 2011
    • ARYx Therapeutics, H2 2011
    • Repligen Corporation, H2 2011
    • SYGNIS Pharma AG, H2 2011
    • Dongwha Pharm Co., Ltd., H2 2011
    • Biotie Therapies Corp., H2 2011
    • Allon Therapeutics Inc., H2 2011
    • Suven Life Sciences Ltd., H2 2011
    • Newron Pharmaceuticals S.p.A., H2 2011
    • Mithridion, Inc., H2 2011
    • Snowdon Inc., H2 2011
    • Domain Therapeutics, H2 2011
    • Critical Pharmaceuticals Limited, H2 2011
    • Curemark, LLC, H2 2011
    • Fabre-Kramer Pharmaceuticals, Inc., H2 2011
    • PsychoGenics, Inc., H2 2011
    • Oakwood Laboratories L.L.C., H2 2011
    • Omeros Corporation, H2 2011
    • Intra-Cellular Therapies, Inc., H2 2011
    • Targacept, Inc., H2 2011
    • N-Gene Research Laboratories, Inc., H2 2011
    • Galenea Corp., H2 2011
    • Marinus Pharmaceuticals, Inc., H2 2011
    • M's Science Corporation, H2 2011
    • BrainCells Inc., H2 2011
    • EUSA Pharma, Inc., H2 2011
    • KemPharm, Inc., H2 2011
    • Heptares Therapeutics Ltd., H2 2011
    • BIOPROJET SCR, H2 2011
    • Reviva Pharmaceuticals Inc., H2 2011
    • SK Bio-Pharmaceuticals, H2 2011
    • PharmaNeuroBoost N.V., H2 2011
    • Assessment by Monotherapy Products, H2 2011
    • Assessment by Combination Products
    • Assessment by Stage and Route of Administration, H2 2011
    • Assessment by Molecule Type, H2 2011
    • Schizophrenia Therapeutics - Drug Profile Updates
    • Discontinued Products
  • List of Figures
    • Number of Products under Development for Schizophrenia, H2 2011
    • Products under Development for Schizophrenia - Comparative Analysis, H2 2011
    • Products under Development by Companies, H2 2011
    • Products under Investigation by Universities/Institutes, H2 2011
    • Late Stage Products, H2 2011
    • Mid Clinical Stage Products, H2 2011
    • Early Clinical Stage Products, H2 2011
    • Discovery and Pre-Clinical Stage Products, H2 2011
    • Assessment by Monotherapy Products, H2 2011
    • Assessment by Combination Products, H2 2011
    • Assessment by Route of Administration, H2 2011
    • Assessment by Stage and Route of Administration, H2 2011
    • Assessment by Molecule Type, H2 2011
    • Assessment by Stage and Molecule Type, H2 2011